Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases Merck to accelerate development of Chord's innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Op... Biopharmaceuticals, Neurology, Mergers & Acquisitions Chord Therapeutics, Merck
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news